BUSINESS

Latuda Succeeds in PIII Schizophrenia Study, Japan NDA Submission Planned by September

January 11, 2019

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

Sumitomo Dainippon Pharma said on January 10 that its atypical antipsychotic Latuda (lurasidone) hit the primary endpoint in a global PIII study enrolling patients with schizophrenia, with the company now planning to file the drug in Japan by the end…

To read the full story

Latuda to Finally Hit Japan Market on June 11
June 5, 2020
After 3rd PIII Try, Sumitomo Dainippon Finally Files Latuda for Japan Approval
August 1, 2019

BUSINESS

Enhertu Accepted for EU Review in Post-Neoadjuvant HER2 Breast Cancer
February 20, 2026
SymBio Receives Grant for Antiviral Brincidofovir
February 20, 2026
Over 40% of Breast Surgeons Largely Unaware of Clinical Trials: Survey
February 20, 2026
Asahi Kasei’s Flagship Teribone to Undergo US Feasibility Review by MAIA
February 20, 2026
Asahi Kasei, Alchemedicine Begin PI Trial of CKD Drug
February 20, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

Hisamitsu’s MBO: Is Shareholder Accountability Trust-Building or a Shackle?

By Hayate Horiguchi

Following Hisamitsu Pharmaceutical’s decision to go private through a roughly 400 billion yen management buyout (MBO), industry observers are weighing…

COLUMN

AI in Healthcare Hiring: Leveling the Playing Field & Unlocking Human Potential

By Philip Carrigan

The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…